IASLC > International Association for the Study of Lung Cancer > About IASLC > News Detail

Phase 1 Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and NonSmall Cell Lung Cancer

Sunday, September 08, 2019


Chris Martin,[email protected] | 630-670-2745
Becky Bunn, [email protected] | 720-325-2946 

Phase 1 Study Shows Novel KRAS Inhibitor Well Tolerated by Patients with Adenocarcinoma and NonSmall Cell Lung Cancer

Barcelona—A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promisingantitumor activity and few adverse side effects in patients with advanced non-small cell lung cancerharboring KRAS G12C mutation, according to research presented today at the IASLC 2019 WorldConference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

The KRASG12C mutation is found in approximately 14 percent of patients with lung adenocarcinoma and11 percent of patients with non-small cell lung cancer but there are no therapies approved that targetthis mutation. KRAS G12C mutation has been identified as an oncogenic driver of tumorigenesis. KRAS isa guanine-nucleotide-binding protein that acts as a molecular switch inside cells and links to receptortyrosine kinase activation to intracellular signaling.

To test this therapy, AMG 510, for safety and toxicity, Ramaswamy Govindan, M.D., from the SitemanCancer Center at Washington University School of Medicine, St. Louis and colleagues enrolled 76patients with locally advanced or metastatic malignancies who had received previous standard therapy.The research group’s primary endpoint was toxicity and secondary research endpoints were objectiveresponse rate, duration of response, disease control rate, progression free survival and duration ofstable disease.

Patients were enrolled in four dose cohorts: 180 mg, 360 mg, 720 mg and 960 mg, taken orally once aday for 21 days and followed up with radiographs and examinations. Initial data from the Phase onestudy were presented at the 55th Annual Meeting of the American Society of Clinical Oncology earlierthis year. The additional follow-up in a larger group of patients being presented at WCLC includes asubset of 34 NSCLC patients enrolled, with 23 of the patients being evaluable for efficacy. Thirteen ofthe evaluable patients received the target dose of 960 mg once daily, with seven (54 percent) achievinga partial response at one or more timepoints and six (46 percent) achieving stable disease, for a diseasecontrol rate of 100 percent.

There were no dose-limiting toxicities and no adverse events leading to discontinuation in the 34 NSCLCpatients enrolled. Twenty-seven of these patients remain on treatment. Of the 34 patients, only nine(26.5 percent) reported treatment-related adverse events (TRAEs) of grade one or two. Three patientsreported grade three treatment-related adverse effects (anemia and diarrhea). There were no gradefour or higher TRAEs.

“KRAS G12C mutant lung adenocarcinoma is one of the largest subsets of NSCLC potentially amenable totargeted therapies. I am pleased that we have a promising new oral therapy for this group of patients,”Govindan said. “These data continue to show encouraging anti-tumor activity with AMG 510,underscoring the potential to close the treatment gap for non-small cell lung cancer patients withpreviously treated KRAS G12C-mutated NSCLC.”

About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracicmalignancies, attracting more than 7,000 researchers, physicians and specialists from morethan 100 countries. The goal is to increase awareness, collaboration and understanding of lungcancer, and to help participants implement the latest developments across the globe. Theconference will cover a wide range of disciplines and unveil several research studies and clinicaltrial results. For more information, visit wclc2019.iaslc.org.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only globalorganization dedicated solely to the study of lung cancer and other thoracic malignancies.Founded in 1974, the association's membership includes more than 7,500 lung cancerspecialists across all disciplines in over 100 countries, forming a global network workingtogether to conquer lung and thoracic cancers worldwide. The association also publishes theJournal of Thoracic Oncology, the primary educational and informational publication for topicsrelevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visitwww.iaslc.org for more information. 


About the Author

Chris Martin, Vice President, Public Relations